Disease Burden of Mild Asthma: Findings from a Cross-Sectional Real-World Survey.
Disease Burden of Mild Asthma: Findings from a Cross-Sectional Real-World Survey.
复制标题
DOI：
10.1007/s12325-017-0520-0
复制
发表时间：
2017-05
影响因子：
3.8
通讯作者：
Small M
中科院分区：
文献类型：
--
作者：
Ding B;Small M
大多数哮喘患者患有轻度疾病，尽管轻度哮喘的负担尚未得到充分了解或研究。一些证据表明，许多轻度哮喘患者的症状控制不佳且病情加重。本研究描述了居住在中国、法国、德国、意大利、日本、西班牙、英国或美国的确诊为轻度哮喘（定义为 GINA 步骤 1 或步骤 2）的患者的疾病负担和治疗模式。呼吸系统疾病特定计划前瞻性横断面调查是与八个国家中每个国家的初级保健医生和专科医生进行的。医生和患者调查评估了人口统计和临床特征、哮喘症状的频率和时间、恶化、救援吸入器的使用、最新的 FEV1% 预测以及医疗保健利用率。 GINA Step 由规定的治疗方案确定。 GINA 步骤 1 患者根据需要服用缓解药物，步骤 2 需要使用低剂量吸入皮质类固醇、白三烯受体拮抗剂或茶碱进行治疗。使用莫里斯基药物依从量表评估治疗依从性，使用哮喘控制测试评估疾病控制，使用工作生产力和活动损伤量表评估工作和活动损伤。样本包括 1115 名 GINA 第 1 步和第 2 步患者，其中 53% 属于第 2 步。总体哮喘控制效果不佳，有夜间症状 (40.6%)、症状恶化 (10.5%) 以及过去 4 周内使用救援吸入器 (33.6%) 的报告。 25%的患者未得到控制。过去 12 个月的总体平均病情加重次数为 0.4 次，其中第 2 步患者的病情加重频率较高，他们也经历了更多需要强化治疗、急诊科就诊或住院治疗的病情加重。轻度哮喘给患者带来沉重负担，需要制定全面的管理计划并持续支持治疗依从性。阿斯利康。
Most asthma patients have mild disease, although the burden of mild asthma is not well understood nor studied. Some evidence suggests that many patients with mild asthma experience suboptimal symptom control and exacerbations. This study characterizes the burden of illness and treatment patterns among patients with a confirmed diagnosis of mild asthma, defined as GINA Step 1 or Step 2, and residing in China, France, Germany, Italy, Japan, Spain, the United Kingdom, or the United States. The Respiratory Disease-Specific Programme prospective cross-sectional survey was conducted with primary care and specialty physicians in each of the eight countries. Physician and patient surveys assessed demographic and clinical characteristics, frequency and timing of asthma symptoms, exacerbations, and rescue inhaler usage, the most recent FEV1% predicted, and healthcare utilization. GINA Step was determined by prescribed treatment regimen. GINA Step 1 patients were prescribed as-needed reliever medication and Step 2 required treatment with a low-dose inhaled corticosteroid, leukotriene receptor antagonist, or theophylline. Treatment adherence was assessed with the Morisky Medication Adherence scale, disease control with the Asthma Control Test, and work and activity impairments with the Work Productivity and Activity Impairment scale. The sample included 1115 GINA Step 1 and 2 patients, with 53% classified as Step 2. Overall asthma control was suboptimal, with reports of nocturnal symptoms (40.6%), symptom worsening (10.5%), and rescue inhaler usage in the last 4 weeks (33.6%). 25% of patients were uncontrolled. The overall mean number of exacerbations in the last 12 months was 0.4, with a higher frequency of exacerbations in Step 2 patients who also experienced more exacerbations requiring treatment intensification, an emergency department visit, or hospitalization. Mild asthma imposes a substantial burden on patients, establishing the need for comprehensive management plans and ongoing support for treatment adherence. AstraZeneca.